Hints and tips:
...Trevor Eliot Bowes is suitably grave as the philosopher tutor Seneca, and Amy J Payne walks away with her scene-stealing opportunity as nurse Arnalta....
...Greater demand for higher-margin premium products, such as J Sainsbury’s Taste the Difference sausages, also helped to lessen the impact of raw material costs....
...Strong international sales helped buoy J&J’s strong fourth quarter, where currency effects accounted for almost a third of the 26 per cent jump in international sales J&J’s fourth-quarter profits, excluding...
...And it is a knee made by J&J’s DePuy, of course....
...J.M.W....
...Progress from J&J’s restructuring programme, which includes about 4,000 job cuts, was a key factor in its new forecast and helped J&J potentially reach the benchmark double-digit earnings growth....
...Christopher Bowe discusses J&J's ambitious restructuring plans, and the role played by US healthcare environment...
...Two of J&J’s most critical products have been affected this year by such concerns....
...Shares in J&J were 2 per cent lower at $62.54 in New York lunchtime trading....
...Today, it is full of gleaming new skyscrapers housing high-profile companies, such as Goldman Sachs and J.P. Morgan Chase. The downtown area, along the river and facing Manhattan, has been rejuvenated....
...Its anaemia drug Eprex/Procrit also continued to suffer due to competition, and J&J’s new drug pipeline has not been smooth....
...They often cost nearly double the price of bare-metal stents, generating more than $5bn in US sales combined for Boston’s Taxus and J&J’s Cypher....
...J.P. Garnier, chief executive of UK drugmaker GlaxoSmithKline, said once that drug salesforces had become an “arms race.”...
...Medical devices have in the past helped J&J offset slowing sales in its pharmaceutical business. J&J said second quarter profit rose 7 per cent to $2.9bn, while its sales rose 5 per cent to $13.4bn....
...Investors cheered J&J's bargaining skills, sending its shares 5 per cent higher to $63.34....
...People familiar with the discussions said that from a handful of bidders, only GSK, the UK pharmaceuticals group, J&J, its US rival, and Reckitt, the British consumer products group, remained in the running...
...Boston bettered J&J’s bid for Guidant with a significantly higher offer worth about $27bn....
...The prospect of a defeat in the Guidant boardroom led J&J to inform Guidant that it was willing to raise its bid. However, the price to which J&J was willing to go, and other terms, were not specified....
...In November, J&J forced Guidant to take a lower price of $21.5bn, or $63 per share. However, J&J’s tough negotiations and the delays they caused gave Boston an opportunity to enter the fray....
...Having initially agreed terms with J&J, Guidant’s board now deems Boston’s offer “superior” to J&J’s....
...Over the past three weeks, J&J and Boston have been trading blows, with each side raising its offer twice before J&J folded on Wednesday. There too, J&J was caught off guard....
...Increased competition, some from J&J’s Cypher stent, could damp its growth....
...Bob Hopkins, analyst at Lehman Brothers, said in a research note: “If the deal value were to drop below $75, J&J might start to look like a better deal, although J&J’s $71 bid no longer necessarily exists...
...than the latest bid from J&J, worth $71 per share, or $24.2bn....
...If J&J walked it meant that everybody was suspicious of what Guidant had underneath.”...
International Edition